[Study on cefotiam in the perinatal period].
Cefotiam (CTM), a new cephem antibiotic with high activity against Gram-positive and Gram-negative bacteria, has been investigated for use in 60 mothers in perinatal period, and following results were obtained. The concentration of CTM in maternal serum was 38 micrograms/ml at 0.5 hour after an intravenous administration of 1 g. A good transport of CTM into umbilical cord serum and amniotic fluid was observed after the intravenous administration into the mother. No adverse effect appeared in the neonates. The CTM is highly useful antibiotic in perinatal infections, and the safe dose of CTM to the mother in perinatal period is considered to be 1-2 g per day.
Takase
Z
Z
Miyoshi
T
T
Fujiwara
M
M
Nakayama
M
M
Komoto
Y
Y
Shirafuji
H
H
D000028:Abortion, Induced; D000653:Amniotic Fluid / Q000378:metabolism; D002439:Cefotaxime / Q000008:administration & dosage / Q000031:analogs & derivatives* / Q000378:metabolism; D015310:Cefotiam; D003475:Curettage; D005260:Female; D005312:Fetal Blood / Q000378:metabolism; D006801:Humans; D007275:Injections, Intravenous; D008413:Mastitis / Q000188:drug therapy*; D008431:Maternal-Fetal Exchange; D008895:Milk, Human / Q000378:metabolism; D011247:Pregnancy / Q000378:metabolism*; D011251:Pregnancy Complications, Infectious / Q000188:drug therapy*; D011645:Puerperal Infection / Q000188:drug therapy*
D015310:Cefotiam; D002439:Cefotaxime